CN116133677A - 新型多肽制剂及其治疗用途 - Google Patents

新型多肽制剂及其治疗用途 Download PDF

Info

Publication number
CN116133677A
CN116133677A CN202180048688.9A CN202180048688A CN116133677A CN 116133677 A CN116133677 A CN 116133677A CN 202180048688 A CN202180048688 A CN 202180048688A CN 116133677 A CN116133677 A CN 116133677A
Authority
CN
China
Prior art keywords
aib
compound
pharmaceutical formulation
amino acid
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180048688.9A
Other languages
English (en)
Inventor
韩捷
沈志超
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hong Xu Biological Medicine Science And Technology Beijing Co ltd
Original Assignee
Hong Xu Biological Medicine Science And Technology Beijing Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hong Xu Biological Medicine Science And Technology Beijing Co ltd filed Critical Hong Xu Biological Medicine Science And Technology Beijing Co ltd
Publication of CN116133677A publication Critical patent/CN116133677A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

本发明涉及多肽化学领域，具体而言本发明涉及一种多肽化合物药物制剂及其在医疗中的用途。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN202180048688.9A 2020-07-06 2021-07-06 新型多肽制剂及其治疗用途 Pending CN116133677A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010643548 2020-07-06
CN2020106435483 2020-07-06
PCT/CN2021/104822 WO2022007809A1 (zh) 2020-07-06 2021-07-06 新型多肽制剂及其治疗用途

Publications (1)

Publication Number Publication Date
CN116133677A true CN116133677A (zh) 2023-05-16

Family

ID=79552785

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180048688.9A Pending CN116133677A (zh) 2020-07-06 2021-07-06 新型多肽制剂及其治疗用途

Country Status (2)

Country Link
CN (1) CN116133677A (zh)
WO (1) WO2022007809A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230125093A (ko) 2021-01-20 2023-08-28 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CN117323410A (zh) * 2022-06-30 2024-01-02 深圳翰宇药业股份有限公司 一种多肽药物溶液制剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ612297A (en) * 2010-12-22 2015-10-30 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
SG11201503526UA (en) * 2012-12-21 2015-06-29 Sanofi Sa Dual glp1/gip or trigonal glp1/gip/glucagon agonists
WO2015086730A1 (en) * 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) * 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086729A1 (en) * 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
MX2021006505A (es) * 2018-12-03 2021-10-01 Antag Therapeutics Aps Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) modificados.
WO2020143625A1 (zh) * 2019-01-07 2020-07-16 鸿绪生物医药科技（北京）有限公司 新型多肽及其治疗用途

Also Published As

Publication number Publication date
WO2022007809A1 (zh) 2022-01-13

Similar Documents

Publication Publication Date Title
US9938335B2 (en) Glucagon and GLP-1 co-agonist compounds
US7601691B2 (en) Anti-obesity agents
EP1934245B1 (en) Y2 selective receptor agonists for therapeutic interventions
AU2012261869B2 (en) Long-acting GLP-1/Glucagon receptor agonists
JP7324530B2 (ja) 新型ポリペプチド及びその治療用途
KR100905380B1 (ko) 신경펩타이드-2 수용체(ｙ２ｒ) 작용물질 활성을 갖는펩타이드
JP2020125311A (ja) Ｇｉｐ誘導体およびその使用
US20230220033A1 (en) Glp-1 agonist polypeptide compound and salt thereof, synthesis method therefor and use thereof
CN107075574A (zh) 铁调素和微型铁调素类似物及其用途
CN105307672A (zh) 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂
US20100021480A1 (en) Bioactive substance-blood protein conjugate and stabilization of a bioactive substance using the same
CN1976948A (zh) 修饰的Exendins及其应用
CN116133677A (zh) 新型多肽制剂及其治疗用途
TW201940504A (zh) 經修飾之脂質化鬆弛素ｂ鏈胜肽及其治療用途
WO2020103729A1 (zh) 胰高血糖素衍生肽及其用途
US20090099074A1 (en) Modulating food intake
CN108676084B (zh) 艾塞那肽的修饰物及其应用
JP2023541798A (ja) Ｃｒｆ２受容体アゴニスト及び治療におけるその使用
US20230263896A1 (en) Novel polypeptide and therapeutic use thereof
CN116650424A (zh) 新型多肽制剂及其治疗用途
CN114891071A (zh) 新型多肽及其治疗用途
WO2023207106A1 (zh) Glp-1/gip受体共激动剂、包含其的药物组合物及其用途
CN115785249B (zh) 一类glp-1类似物及其应用
CA3230915A1 (en) New peptides as potent and selective gip receptor agonists
CN117756913A (zh) 一种新型长效多肽化合物、组合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination